Clinical Trials

The Shamrock Trial

Breast Cancer Ireland is supporting The Shamrock Trial, focussing on HER2+ patients with recurrence. The trial uses a new 4th generation drug, Deruxtecan, combined with initial chemotherapy. After one month it is hoped to de-escalate the use of chemotherapy and continue with the drug, and it is anticipated that after a 2-3 year period we will see a 100% response rate in patients — a cure for this particular subtype.